
#### **COVID-19 Vaccination Plan**

#### **South Dakota Department of Health**

February 23, 2021



We will begin in just a few moments. Thanks! *Information is current as of 02.22.2021* 



This is an **emerging**, **rapidly evolving situation**. Information in this presentation is current as of February 22, 2021. Please check the South Dakota Department of Health website for the most current information and guidance.

**COVID.sd.gov** 



## **Agenda**

Update on Vaccination – Tim Heath

SDIIS Updates – Brett Oakland

Training Update – Carol Chalcraft



## **Update on Vaccination**

## **Doses Administered**

Total Doses Administered

185,635

Manufacturer	# of Doses
Moderna	97,706
Pfizer	87,929

Total Persons Administered a Vaccine

123,049

Doses	# of Recipients ▼
Moderna - Series Complete	32,708
Moderna - 1 dose	32,290
Pfizer - Series Complete	29,878
Pfizer - 1 dose	28,173

Percent of State
Population with at least
1 Dose

18%

Doses	% of Pop.						
1 dose	17.83%						
Series Complete	9.07%						
Based on 2019 Census Estimate for							
those aged 16 years ar	nd older						



## **SD DOSES Received**

Pfizer 1	59,085
Pfizer 2	44,265
Moderna 1	71,800
Moderna 2	47,500
LTC Pharm	24,050
Total	246,700



## **SD DOSES Received**

This Weeks 1st dose shipments	17,660
This Weeks 2 <sup>nd</sup> dose Shipments	15,190
Doses At Pharmacy	10,323
Second Dose to be given this week	17,000



## Weekly 1st Doses Projected

**Pfizer** 9,360

Moderna 8,300



#### **Bonus Doses**

Pfizer vaccine yields 6 doses – this will be a label change

Moderna vaccine may yield 1 or 2 extra doses

DO NOT POOL VACCINE FROM MULTIPLE VIALS



#### **Priority groups**

https://doh.sd.gov/documents/COVID19/Vaccine/COVIDV accineAvailability\_Distribution\_FlyerSize.pdf

1A 19,265 22,816 Vaccinated

1B 10,867 2,975 Vaccinated-not including CVS/Walgreens

1C 49,642 23,375 Vaccinated

1D 265,561 56,386

1E 227,448



#### Expected COVID-19 Vaccine Availability for South Dakota Residents

Phase	Population Group	January	February	March	April	May-December
1A	Frontline healthcare workers and long-term care facility healthcare workers					
18	Long-term care residents					
1C	EMS, public health workers, and other healthcare workers (lab & clinic staff)					
10	Law enforcement, correctional officers					
N	Persons aged 65 years and older Starting (02/22/21) – Those 65 and over					
1D 1D	High risk patients - dialysis, post-transplant, and active cancer					
ó	High risk residents in congregate settings					
	Persons with 2 or more underlying medical conditions under the age of 65					
1D	Teachers and other school/college staff					
	Funeral service workers					
1E	Fire service personnel					
16	Includes public-facing workers in essential and <u>critical infrastructure</u>	Esti				
Phase 2	All others 16 years and older	Note: Tribal vaccine al	llocation & administration is ha allocation & administration is i	andled by the <u>IHS</u>		

Due to limited allocation of the vaccine, the South Dakota Department of Health will use COVID-19 infection rates and will follow recommendation: from the Advisory Committee on Immunization Practices (ACIP) to guide which counties will receive the vaccine first.






AS OF 02-17-21

https://doh.sd.gov/documents/COVID19/Vaccine/COVIDV accineAvailability\_Distribution\_FlyerSize.pdf






https://doh.sd.gov/COVID/Vaccine/ProviderMap/default.aspx



## South Dakota: All Federal Pharmacy Partners



DRAFT - PRE-DECISIONAL & DELIBERATIVE

CVS

Cardinal

Walgreens

Topco

Walmart

CPESN

Rite Aid

- ABC
- Kroger Corporate Pharmacy
- MHA

Albertsons

- Health Mart
- Publix Super Markets
- Gerimed
- Retail Business Services
- Innovatix

- COSTCO
- H-E-B
- Hy-Vee
- Meijer Pharmacy
- Southeastern Grocers
- PharMerica
- Lewis Drug



#### **Federal Partners in SD**

	First Dose	Second Dose	Total
ВОР	100	97	197
VA	11,631	4,258	15,889
IHS	15,511	7,849	23,360
DOD	1,518	1,047	2,565
Totals	28,760	13,251	42,011

#### Janssen/Johnson & Johnson Vaccine

- Have applied for EUA
- FDA to meet on February 26
- Viral Vector vaccine
- 5 dose vials



## **SDIIS Updates**



- SDIIS Training: <a href="https://doh.sd.gov/COVID/Vaccine/Providers.aspx">https://doh.sd.gov/COVID/Vaccine/Providers.aspx</a>
- The following trainings are available for new users and serve as a review for skilled users. Data Entry staff, whether vaccinators or ancillary staff, should view, at minimum, Trainings 1, 2, and 3. Staff tasked with Data Entry and Inventory Management, e.g. Vaccine Coordinators, should view all SDIIS trainings.
- <u>User Application</u> (next slide)
  - 1. Login and Settings (updated 12/02/20)
  - 2. Search for Patients and Edit Information (updated 02/08/21)
  - 3. Give Vaccine (updated 01/11/21)
  - 4. Ordering and Receiving (updated 02/01/21)
  - Inventory Management (updated 12/28/20)
     Wastage Reconciliation (01/26/21)
  - 6. Vaccine Transfer (updated 01/12/21)
  - 7. Patient Detail Report (01/05/21)



#### South Dakota Immunization Information System (SDIIS) USER ACCESS ACCOUNT APPLICATION

Please complete this form to request a user account for each staff member who needs access to the SDIIS. Upon completion and return of this form, a USER ID and temporary PASSWORD will be assigned. Once the credentials have been assigned, we recommend you change your password after you log in for the first time. Password: Passwords should be AT LEAST characters and include a combination of letters, numbers, and special characters. PLEASE DO NOT SHARE PASSWORDS AND USER ACCOUNTS. If you have questions, please contact Brett Oakland at (605) 367-4902 or Radhi Saripalli at (605) 773-7473. Retain a copy of this form in your files and email the completed form to <a href="mailto:brett.oakland@state.sd.us">brett.oakland@state.sd.us</a> or fax to (605) 367-5357.

#### SDIIS USER ACCESS ACCOUNT INFORMATION

First Name:(List your name as you'd like					_			
Name of Clinic/ Facility: _					_			
SDIIS PIN:	Р	hone Num	ber:	Ext	_			
Individual Email Address:					_			
		(Share	ed email accounts	are not acceptable)				
Access Required: New User Existing User  View only – view and print record, but cannot add immunizations or edit record  Data Entry - enter immunizations and edit patient records, but no access to inventory  Inventory Management - enter immunizations, edit patient records, access to facility inventory								
Does user float between clinic sites? (Check one): ☐ Yes ☐ No (If yes, a separate application must be completed for each clinic)								
VACCINATOR STATUS:	ering vaccinat	ions for tl	his facility.					
lam: □ RN	□ CMA	□ PA	☐ Pharmacist	□ Other				
	□ MD/DO							
□ I will NOT be adm	inistering vac	cinations	for this facility.					

#### SDIIS User Access Application


- <mark>UPDATED:</mark>
- Used to request access for new users to SDIIS
- Used for those who to need view/enter data into the SDIIS
- **NEW:** Section regarding vaccinator status
- Has been added to Provider Education website
- https://doh.sd.gov/COVID/Vaccine/Providers.aspx



#### • COVID-19 Vaccine Data Entry Reminders

- Use simple search parameters when searching for patients in SDIIS.
  - Use first initial and birthdate, or
  - Use first three letters of first and last name
  - Remember to consider given name vs. nickname e.g. James vs. Jim
  - Please ensure that the **name and birthdate match** the person who is vaccinated. Check address and phone, anything to help confirm patient identity
  - Avoid creating duplicate records.
  - If multiple patient searches come up empty, then you may ADD NEW PATIENT
- When selecting priority group, DO NOT select Priority Group "2nd Dose" if patient record does not already have
  one dose. If you know the patient received a first dose, but you don't see it, then you don't have the right record.
- Ensure that the 2<sup>nd</sup> dose of COVID-19 vaccine is the same brand as the first dose
- ALL COVID-19 vaccine records in SDIIS must have an ADDRESS (City, State, Zip, County)
- ALL COVID-19 vaccine records in SDIIS must include GENDER, RACE, ETHNICITY (Hispanic Origin in SDIIS)





#### • Edit Patient Information

- Click EDIT under PATIENT INFORMATION section
- The EDIT PATIENT INFORMATION screen will appear



#### EDIT PATIENT INFORMATION Bert Oak DOB: 1/1/1940 SYSTEM IDENTIFIER: 140-00002-1505381 LAST CLINIC: Test Clinic 2010 (#7734) LAST UPDATED: 11/11/2020 12:35:46 PM DATE OF ENTRY: 11/9/2020 5:58:59 PM PATIENT INFORMATION LAST NAME : Oak FIRST NAME : Bert MIDDLE NAME: Jim SUFFIX: ALIAS (NICKNAME): TESTRECORD DATE OF BIRTH: 1/1/1940 STATE/COUNTRY OF BIRTH: GENDER: Male RACE: Native American EDI HISPANIC ORIGIN: Non-Hispanic LANGUAGE: VFC ELIGIBILITY: Not Eligible OTHER PROGRAMS: EDIT SOCIAL SECURITY #: SCHOOL DISTRICT: CONFIRM SSN:

PATIENT STATUS : Active
HEALTH PLAN : EDIT


OCCUPATION: SELECT

CHART#:

#### Edit Patient Information

- Please enter the following, which are
   REQUIRED for COVID-19 Vaccination Plan,
  - Confirm name, date of birth
  - Gender
  - Race click EDIT and choose
  - Ethnicity click HISPANIC ORIGIN dropdown
    - Choose non-Hispanic, if so
    - Choose Unknown Hispanic, if Hispanic, but origin unknown
- VFC Eligibility choose NOT ELIGIBLE for all adults; choose best option for 18 and under
  - Not required for COVID-19 vaccine documentation, but SDIIS requires this field to be completed.
- Click UPDATE






#### Edit Contact Information

- Click EDIT under CONTACT INFORMATION section
- The **EDIT CONTACT & GENERAL INFORMATION** screen will appear






#### Edit Contact Information

- Please enter the following:
  - Parent & Guardian Information for clients under age 18 (SSN's not necessary)
  - REQUIRED for COVID-19 Vaccination Plan
     PATIENT ADDRESS click EDIT
  - EDIT PATIENT ADDRESS screen will appear; see next slide.
  - Click UPDATE when address is complete
- Enter phone numbers no dashes XXXXXXXXXX
- May enter Primary Care Physician information, if known
- Click **UPDATE**






#### • Edit Contact Information

- Please enter the following:
  - EDIT PATIENT ADDRESS screen
  - Complete ADDRESS and ZIP CODE fields
  - Click **SUBMIT** next to the **ZIP CODE** field. The proper **state**, **county**, and **city** should be highlighted. If not, please correct.
  - ADDRESS LINE 2 Do not enter City, SD this is for and extension of the street address, e.g., "PO Box xx", "Apt #", etc.
  - Click UPDATE when address is complete

 NOTE: If a recipient refuses to provide ADDRESS please obtain, at minimum, the ZIP CODE. With the ZIP CODE field, we can ascertain state, county, and city. You MUST click SUBMIT next to the zip code.






- Vaccine Transfer
  - Receiving Facility
- Click INVENTORY
- The **EDIT INVENTORY** screen will appear

CLOSE INVENTORY

#### EDIT INVENTORY



- Vaccine Transfer
  - Receiving Facility
- Shows entire inventory, including existing inventory of same lot number being transferred, OR, if no previous inventory of lot, new inventory item with "0" count
  - Click on blue hyperlink of vaccine name
  - In the **EDIT INVENTORY ITEM** screen, you can see that a shipment is "In Transit"
  - Click SHIPMENTS
  - The **EDIT SHIPMENTS** screen will appear

Not intended for press or for reporting purposes.



# CHOOSE CLINIC STATUS Central Registry Not Closed VACCINE FUNDING SOURCE Total Final Final

#### Vaccine Transfer

- Receiving Facility
- **STATUS** field should be "Not Closed"
  - If Shipment does not appear, change STATUS to Complete, and see if the shipment is in that list.
- Click blue hyperlink (Order #)
- The **EDIT SHIPMENT** screen will appear

#### **EDIT SHIPMENT**



- Click **RECEIVE SHIPMENT**
- The RECEIVE SHIPMENT screen will appear

Not intended for press or for reporting purposes.



#### RECEIVE SHIPMENT




#### **EDIT SHIPMENT**



- Vaccine Transfer
  - Receiving Facility
  - Enter TOTAL DOSES RECEIVED
- Is this shipment complete?
  - **YES** if received all doses
  - **NO** if mores doses pending
- Click UPDATE
- The **EDIT SHIPMENT** screen will reappear
- Confirm details
- STATUS automatically changes to indicate shipment Complete
- VOL SHIPPED = VOL RECEIVED
- Click UPDATE
- The **EDIT SHIPMENTS** screen will reappear





- Vaccine Transfer
  - Receiving Facility
- Receiving facility's inventory reflects the change
- Click CANCEL
- The **EDIT INVENTORY** screen will reappear

#### EDIT INVENTORY



- Receiving facility's inventory reflects the change
- Click CLOSE INVENTORY



## **Training Update**



#### **NEEDED: Education Attestations**

Thanks to all providers who have submitted Education Attestations

If your provider site has not submitted the Attestation, please do ASAP

If you need assistance with submitting the Attestation, please contact me.





#### MEMORANDUM

To: Whom It May Concern

From: Moderna

Re: Moderna COVID-19 Vaccine Vials

The Moderna COVID-19 Vaccine (aka "COVID-19 Vaccine Moderna") has traditionally been filled and distributed in clear vials. In order to best meet the vaccine preparation demands of the COVID-19 pandemic, Moderna has engaged multiple vial sources including SiO2 Materials Science. SiO2 Materials Science produces polymer-based vials which may appear thicker and display a slight green tint as a result of the vial sterilization process during manufacturing. This tinting is strictly visual and has no impact on the vaccine. Over time, vial tinting may fade naturally, resulting in a faint yellow color. Below are images demonstrating a range of vial colors under various lighting conditions that may be encountered in the field.









Typical range of coloration of Cyclic Olefin Polymer (COP) vials, SiO2 Materials Science, 2020

The Moderna COVID-19 Vaccine has not been approved or licensed by the U.S. Food and Drug Administration (FDA), but has been authorized for emergency use by FDA, under an Emergency Use Authorization (EUA), to prevent Coronavirus Disease 2019 (COVID-19) for use in individuals 18 years of age and older. There is no FDA-approved vaccine to prevent COVID-19. The EUA for the Moderna COVID-19 Vaccine is in effect for the duration of the COVID-19 EUA declaration justifying emergency use of the product, unless the declaration is terminated or the authorization is revoked sooner.

For information on the authorized use of Moderna COVID-19 Vaccine and mandatory requirements of the EUA, please review the Fact Sheet for Healthcare Providers Administering Vaccine and full Prescribing Information.

Moderna Medical Information Letter Effective February 2021



#### Pfizer-BioNTech Live Training

#### Live Training

Pfizer also provides live training sessions to review information and answer your questions about the Pfizer-BioNTech COVID-19 Vaccine. Click on a link below to join the session at the designated time. Each <u>training-offers</u> the same content.

Date & Time	•	Password
Attendee link – February 23 – 5 PN	<u> </u>	37mRTyyPB6N
Attendee link – February 24 – 10 A	M ET	gnB62EA82pv

#### Risk for COVID-19 Infection, Hospitalization, and Death By Age Group

Rate compared to 5–17-years¹	0–4 years	5–17 years	18–29 years	30–39 years	40–49 years	50–64 years	65-74 years	75–84 years	85+ years
Cases <sup>2</sup>	<1x	Reference group	3x	2x	2x	2x	2x	2x	2x
Hospitalization <sup>3</sup>	2x	Reference group	7x	10x	15x	25x	35x	55x	80x
Death⁴	2x	Reference group	15x	45x	130x	400x	1100x	2800x	7900x

All rates are relative to the 5–17-year age category. Sample interpretation: Compared with 5–17-year-olds, the rate of death is 45 times higher in 30–39-year-olds and 7,900 times higher in 85+-year-olds. Compared with 18–29-year-olds, the rate of hospitalization is 8 times higher in 75–84-year-olds (55 divided by 7 equals 7.9).

#### How to Slow the Spread of COVID-19



Wear a mask



Stay 6 feet apart



Avoid crowds and poorly ventilated spaces



Wash your hands

cdc.gov/coronavirus

CS319360-A 02/18/2021





## Older adults and people with disabilities who may need additional support to get vaccinated

- Homebound
- Living with cognitive impairment or decline
- Living with mobility challenges, vision or hearing loss, or other disabilities
- Living in congregate or crowded settings, such as group homes and independent living facilities for older adults
- Living in remote, rural, or tribal areas
- Without family or community support to help them find out about vaccines
- Without access to the internet or unable to use online scheduling systems
- In an ethnic, racial, or other group at higher risk for COVID-19
- Not native English speakers



#### Homebound persons need special considerations

- Medicare (CMS) considers someone homebound if:
  - They need the help of another person or medical equipment such as crutches, a
    walker, or a wheelchair to leave their home, or their doctor believes that their
    health or illness could get worse if they leave their home, AND
  - It is difficult for them to leave their home and they typically cannot do so.
- Approximately 21% of adults 65 years and older were homebound in 2011 Medicare beneficiary survey.
- Newly posted guidance for vaccination of homebound persons for HCP who vaccinate persons who are homebound: www.cdc.gov/vaccines/covid-19/clinical-considerations/homeboundpersons.html.

Ornstein KA, et al. *JAMA Intern Med*. 2015;175(7):1180-1186. doi:10.1001/jamainternmed.2015.1849. Published online May 26, 2015.

The homebound requirement - Medicare Interactive.

2/16/2021



### Ensure vaccination locations are accessible

#### Ensure vaccination clinics:







- Have interpreters available
- Have personnel familiar with working with older adults and people with disabilities
- Are accessible to people relying on assistive equipment or wheelchairs (e.g., handrails, service animals, ramps)
- Follow CDC recommendations for preventing the spread of COVID-19, such as social distancing, and mask wearing for those able to wear a mask
- Provide sufficient seating for those waiting for vaccination and during the postvaccination observation period.
- Incorporate accessibility considerations into planning for walkin, curbside, drive-through, and other types of vaccination clinics.



- Guidance for vaccinating older adults and people with disabilities at vaccination clinics
- What Older Adults Need to Know about COVID-19 Vaccines Communication Resources for COVID-19 Vaccines





#### Healthcare providers are required by law to report to **VAERS**

- Any adverse event listed in the <u>VAERS Table of Reportable Events Following</u>
   <u>Vaccination</u> that occurs within the specified time period after vaccination
- An adverse event listed by the vaccine manufacturer as a contraindication to further doses
  of the vaccine

#### Healthcare providers are **strongly encouraged to report**:

- Any adverse event that occurs after the administration of a vaccine licensed in the United States, whether or not it is clear that a vaccine caused the adverse event
- Vaccine administration errors



### Subject: example of dosage error

By <u>Jackson Cote</u> | <u>jcote@masslive.com</u>

Multiple patients who went to a CVS location in Massachusetts this week to get their <u>coronavirus</u> shots were given wrong dosages of the vaccine, according to the company.

A "limited number" of patients at the company's pharmacy on Central Street in Ipswich were inadvertently given 0.3 milliliter doses of the COVID-19 vaccine instead of the correct 0.5 milliliter doses recommended by the U.S. Centers for Disease Control and Prevention, a spokesperson for CVS told MassLive in a statement.

It is unclear exactly how many people were affected by the mistake.

"We have contacted all affected patients to apologize for this incident and answer any questions they might have," the spokesperson said. "We've reported it to the appropriate regulatory agencies and have taken the necessary steps to prevent this from occurring again."

The spokesperson noted that based on CDC and clinical guidance, another dose of the vaccine is not recommended for the patients who were impacted by the company's error. The people who were affected can get their previously scheduled second shot next month, according to the spokesperson.

<u>WCVB</u> reported a woman who received her vaccine for the viral respiratory infection Monday at the Ipswich location was contacted by a CVS pharmacist, who told her she was given the dosage for the Pfizer-BioNTech vaccine, which is less than the Moderna vaccine.

According to the CDC's website, the dosage for Pfizer-BioNTech's vaccine is 0.3 milliliters, while Moderna's is 0.5 millileters.



#### CDC Topline Points on the First Month of COVID-19 Vaccine Safety Data

- Data from the first month of COVID-19 vaccine safety monitoring provides reassurance about the safety of COVID-19 vaccines currently being used in the United States, as well as helpful information regarding what to expect following vaccination.
- The initial post-authorization safety profiles of the two COVID-19 vaccines in current use did not find evidence of unexpected reporting patterns or safety concerns.
- During this time, more than 13.5 million doses were administered.
- Since the vaccines were authorized in December 2020, safety monitoring for these vaccines has been the most intense and comprehensive in U.S. history.
- In this report, investigators described data from two vaccine safety monitoring systems: the Vaccine Adverse Events Reporting System (VAERS) and v-safe.



# **VAERS** reports

- The Vaccine Adverse Event Reporting System (VAERS) received and processed nearly 7 thousand reports of adverse
  events.
- 90.8% of reports to VAERS were non-serious.
- Reports of severe allergic reactions (anaphylaxis) were rare.
- Common symptoms reported to VAERS after vaccination included local reactions such as pain where the shot was given and reactions affecting other parts of the body (systemic reactions), such as headache, fatigue, and dizziness.
- VAERS also received 113 reports of death following vaccination (65% were among long-term care residents).
- Death reports with available information (including death certificates, autopsy reports, medical records, clinical descriptions from VAERS reports as well as information from healthcare providers) did not suggest a causal relationship between COVID-19 vaccination and death.
- No unexpected patterns or safety concerns have been identified during early monitoring.



## **Transporting COVID-19 Vaccine**

- CDC does not recommend routine transport of vaccines. Ideally, vaccines should be delivered directly to the facility where they will be used.
- If vaccines must be transported, follow storage and handling best practices to ensure the cold chain is maintained:
  - Well-trained staff
  - Appropriate equipment to store the vaccine and monitor temperatures:
    - Portable freezer, refrigerator, or container qualified to maintain the proper temperatures.
    - Digital data logger (DDL) to monitor temperatures with a buffered probe (external display preferred).
  - Written policies and procedures.




# **Transporting mRNA Vaccines Best Practices**

- Protect vaccines as much as possible from drops, shocks, and vibration.
  - To minimize movement, transport in the carton whenever possible.
  - If individual vials are transported, vials should be placed with dunnage (padding material like bubble wrap or similar padding).
  - Secure storage containers during transport.
- Store vaccine vials upright whenever possible.



# **Update: Temperature Monitoring Guidance During Transport**

- Most DDLs display minimum/maximum (min/max) temperatures.\*
- Record the time and min/max temperatures:
  - At the start of transport
  - Every time the storage container is opened
  - When transport is completed
- The total time for transport alone or transport plus clin workday should be a maximum of 8 hours.<sup>±</sup>
  - Beyond-use date/time, if applicable, are included in transport time.



temperature for 120 hours, transport is included in this time frame.



- After packing the vaccine, open the portable storage container only when necessary
- If using a company or personal vehicle, transport vectores inside the passenger compartment inst in the trunk or bed of a truck, which may be too hot or too cold.

is in the portable storage container

- Avoid leaving the portable storage container in direct sunlight or unattended.
- \* If needed, transport diluents with their corresponding voccines to ensure there are equal amounts of voccines and diluents. Follow the manufacturer's guidance for specific temperature requirements for diluents.
- Save this record for 3 years, unless your state/local jurisdiction requires a longer time period. See CDC's Veccine Storage and Handling Too Notifer additional guidance.
- Refer to CDCs Vaccine Storage and Handling Toolkit for additional guidance who transporting vaccines.
- \*If the DOL do as not measure min/max temps entures, check and record temperatures hours ÷ Follow the menufacturer's guidence Fit differs from this time frame.




### **Predrawn Syringes**

- Label both predrawn syringes and container (e.g., resealable plastic bag) used to hold the syringes with:
  - Name of the product and dosage (amount)
  - Exact beyond-use date and time
  - Lot number
  - Preparer's name/initials
- Follow temporary storage container and temperature monitoring guidance.
  - Moderna: Predrawn syringes can either be stored for 6 hours in the refrigerator at 2°C to 8°C (36°F to 46°F) or at ambient room temperature at 15°C to 25°C (59°F to 77°F) after the vial is initially punctured.
  - Pfizer-BioNTech: Predrawn syringes can be stored for 6 hours at 2°C to 25°C (36°F to 77°F) after the vaccine is mixed.



# Moderna COVID-19 Vaccine: Transporting Unpunctured Vials

- Frozen transport: Between -15°C and-25°C (-13°F and 5°F)
  - Frozen transport is preferred.
  - Handle vaccine with care and package securely to minimize shaking and avoid breakage.
- Refrigerated transport: Between 2°C and 8°C (36°F and 46°F) for up to 12 hours (cumulative).
  - Take care to ensure vaccine does not refreeze.
- Beyond-use date labels have been updated to include transport time.





### **Moderna COVID-19 Vaccine: Transporting Punctured Vials**

- Transport punctured vials between 2°C and 8°C (36°F and 46°F).
- Once punctured, the vaccine must be administered within 6 hours.
  - Time used for transport counts as part of the 6-hour time limit.
  - Any vaccine remaining after 6 hours must be discarded.



### **Ancillary Kit for Pfizer-BioNTech COVID-19 Vaccine**

- Ancillary kit supplies have been reconfigured to support 6 doses per multidose vial.
- 1-inch needles and syringes are low dead-volume.
- 1.5-inch needles are NOT low dead-volume.
- Use the correct needle length to ensure the vaccine is administered in muscle tissue.



#### Vaccine Administration: **Needle Gauge and Length**

Vaccines must reach the desired tissue to provide an optimal immune response and reduce the likelihood of injection-site reactions. Needle selection should be based on the: Gender and weight for adults (19 years and older)

The following table outlines recommended needle gauges and lengths, in addition, clinical judgment should be used when selecting needles to administer injectable vaccines.

Route	Age	Needle gauge and length	Injection site
Subcutaneous Injection	All ages	23-25-gauge 5/8 inch (16 mm)	Thigh for infants younger that 12 months of age!; upper outer triceps area for persons 12 months of age and older
Intramuscular Injection	Neonate, 28 days and younger	22–25-gauge 5/8 inch (16 mm²)	Vastus lateralis musde of anterolateral thigh
	Infants, 1–12 months	22-25-gauge 1 inch (25 mm)	Vastus lateralis musde of anterolateral thigh
	Tockilers, 1–2 years	22–25-gauge 1–1,25 inches (25–32 mm)	Vastus lateralis muscle of anterolateral thigh <sup>3</sup>
		22-25-gauge 5/8 <sup>2</sup> -1 inch (16-25 mm)	Deltoid muscle of arm
	Children, 3–10 years	22-25-gauge 5/8 <sup>2</sup> -1 inch (16-25 mm)	Deltoid muscle of arm <sup>2</sup>
		22–25-gauge 1–1.25 inches (25–32 mm)	Vastus lateralis muscle of anterolateral thigh
	Children, 11–18 years	22–25-gauge 5/82–1 inch (16–25 mm)	Deltoid muscle of arm <sup>3,5</sup>
	Adults, 19 years and older = 130 lbs (60 kg) or less = 130-152 lbs (60-70 kg) = Men, 152-260 lbs (70-118 kg) = Women, 152-200 lbs (70-90 kg) = Men, 260 lbs (18 kg) or more = Women, 200 lbs (90 kg) or more	22-25-gauge 1 Inch (25 mm <sup>4</sup> ) 1 inch (25 mm) 1-1.5 inches (25-38 mm) 1-1.5 inches (25-38 mm) 1.5 inches (38 mm) 1.5 inches (38 mm)	Deltoid muscle of arm <sup>3,5</sup>

comment a S-8-inch need oformen and women weighing less than (Oleg. Pus ed, domnest he strict hed tightly and subcuts needs tibuse mest not be bunche helb messle in the anheolobe of this his as de his as ed. Most ad chapum baset adults will apply a 1-to 13-helb (25-16 mm) media to ensure helbamussular admir

Reference: Advisory Committee on Immunization Practices Ceneral Best Practice Guidelines for Immunization www.cdc.gov/vaccines/hca/acip-recs/general-recs/administration.html






# Pfizer-BioNTech COVID-19 Vaccine: Transporting Unpunctured Vials

- Ultra-cold transport: Between -80°C and -60°C (-117°F and -76°F)
- Only full trays of vaccine may be transported at ultra-cold temperatures.
  - Store trays upright whenever possible.
- Temperature monitoring:
  - Thermal shipping container: Use the Controlant temperature monitoring device.
  - Portable ultra-cold freezer: Use a DDL with a probe designed to measure ultra-cold temperatures.



# Pfizer-BioNTech COVID-19 Vaccine: Transporting Unpunctured Vials

- Refrigerated transport: Between 2°C and 8°C (36°F and 46°F)
  - Individual vials or partially filled trays must be transported at refrigerated temperatures.
  - Take care to ensure vaccine does not refreeze.
- Vaccine may be stored at refrigerated temperatures for up to 120 hours (5 days).
  - Any time used for transport counts as part of the 120-hour limit.
  - Beyond-use date labels track this time frame.





# Pfizer-BioNTech COVID-19 Vaccine: Transporting Punctured Vials

- Transport punctured vials between 2°C and 8°C (36°F and 46°F).
  - Take care to ensure vaccine does not refreeze.
- Once mixed, the vaccine must be used within 6 hours.
  - Time used for transport counts as part of the 6-hour time limit.
  - Any vaccine remaining after 6 hours must be discarded.



Vaccine Storage and Handling Toolkit




SOUTH DAKOTA DEPARTMENT OF

Nexte 201



## **Ancillary Kit Reminders**

- When unpacking supplies:
  - Keep supplies for each vaccine product separate. Do not mix needles and syringes.
- Pfizer-BioNTech COVID-19 vaccine only:
  - Keep mixing needles and syringes separate from those for administration.
  - Tell staff to look for the green label on the box containing mixing supplies.



## **Contact Information**

**Angela Jackley** Deputy Administrator, Office of Disease Prevention Services. Vaccination Lead

**Tim Heath** Immunization Program Coordinator, Vaccination colead <a href="mailto:tim.heath@state.sd.us">tim.heath@state.sd.us</a>

**Brett Oakland** Immunization Registry Coordinator <a href="mailto:brett.oakland@state.sd.us">brett.oakland@state.sd.us</a>

Carol Chalcraft Immunization Education Coordinator carol.chalcraft@state.sd.us

Misty Pickner Vaccine Management Specialist misty.pickner@state.sd.us

